HIF Pathway and Fibrosis: How Hypoxia Drives Chronic Organ Damage and Creates Drug Targets

1. Hypoxia and Fibrosis: An Inseparable Pair

Nearly all chronic organ damage involves reduced tissue oxygenation. The renal tubulointerstitium, the centrilobular zone (zone 3) of MASH liver, and the fibrotic foci of IPF lung all become locally hypoxic through microvascular rarefaction.

Under hypoxia, HIF (Hypoxia-Inducible Factor) serves as the master regulator. While HIF originally evolved as an adaptive rescue system for cellular oxygen shortage, chronic activation converts it into a driver of fibrosis — a duality that is central to its disease biology.

This article outlines HIF's molecular machinery, organ-level fibrosis evidence, crosstalk with TGF-β/Smad and YAP/TAZ, and the current drug development landscape.

2. Molecular Machinery of the HIF Pathway

The HIF Family

HIF is an α/β heterodimeric transcription factor.

• HIF-α subunits: oxygen-dependent regulatory subunits
  • HIF-1α: broadly expressed; dominates the acute hypoxic response
  • HIF-2α (EPAS1): restricted to endothelium, liver, proximal renal tubules, and a few other tissues; critical for chronic hypoxic response
  • HIF-3α: splice variants can inhibit HIF-1/2α
• HIF-1β (ARNT): constitutively expressed and nuclear

Oxygen Sensing by VHL-PHD

Under normoxia:

1. PHD (Prolyl Hydroxylase Domain) enzymes hydroxylate two proline residues on HIF-α
2. pVHL (von Hippel-Lindau) binds the hydroxylated HIF-α
3. Ubiquitination and proteasomal degradation follow

Under hypoxia, PHD activity falls → HIF-α is stabilized → translocates to the nucleus → dimerizes with HIF-β → binds HRE (Hypoxia Response Element) → induces target genes.

HIF Target Genes Relevant to Fibrosis

• VEGF, ANGPT2: aberrant angiogenesis
• CTGF (CCN2): myofibroblast activation
• PAI-1: suppresses ECM degradation
• LOX, LOXL2: collagen cross-linking
• PDGF-B, TGFB2: pro-fibrotic cytokines
• COL1A1, COL3A1: direct collagen induction

3. Crosstalk with Major Pathways

HIF × TGF-β

• Hypoxia amplifies TGF-β/Smad signaling, forming a mutually reinforcing loop
• TGF-β itself induces HIF-1α, even under normoxia

HIF × YAP/TAZ

• Hypoxia activates YAP/TAZ, which cooperates with HIF-1α to drive fibrotic gene expression
• Stiff ECM → YAP/TAZ activation → further HIF stabilization: a "stiffness → hypoxia → fibrosis" feed-forward loop

HIF × Notch

• Notch signaling is induced by HIF targets and drives EMT/EndMT
• HIF-2α–Notch axis is particularly prominent in renal fibrosis

4. Organ-Level Evidence

Kidney: The Central Mechanism of CKD

• "Chronic Hypoxia Hypothesis" (Nangaku 2006): glomerular sclerosis → loss of peritubular capillaries → tubulointerstitial hypoxia → fibrosis
• Proximal-tubule–specific Hif1a activation accelerates fibrosis in mice
• Conversely, HIF-PHIs (PHD inhibitors) at moderate doses may combine anemia correction with renoprotection (see below)

Liver: MASH and Cirrhosis

• Hepatic zone 3 (pericentral) is physiologically the most hypoxic — worsened by MASH
• Hepatic stellate-cell–specific Hif1a knockout attenuates CCl4-induced liver fibrosis (Moon et al. 2009)
• Adipocyte hypoxia in fatty liver drives HIF-1α–dependent inflammation

Lung: IPF and Vascular Remodeling

• IPF fibroblastic foci are hypoxic internally
• HIF-1α promotes EMT, contributing to type II alveolar-cell → myofibroblast transition
• In IPF with pulmonary hypertension, HIF-2α is central to vascular smooth-muscle remodeling

Heart: Pressure-Overload Fibrosis

• TAC (transverse aortic constriction) transiently elevates cardiac HIF-1α, promoting fibrosis
• Short-term activation can be cardioprotective — temporal dependence is key to interpretation

5. Drug Development: HIF-PHIs and Anti-Fibrosis

Roxadustat: The First HIF-PHI

• Mechanism: inhibits PHD1/2/3 → HIF-α stabilization → erythropoietin (EPO) induction
• Indication: anemia in chronic kidney disease
• Approvals: China (2018), Japan (2019, FibroGen/Astellas), EU (2021). Not approved by the US FDA (2021, cardiovascular safety concerns)
• Class members: Vadadustat (Mitsubishi Tanabe), Daprodustat (GSK), Enarodustat (JT/Torii), Molidustat (Bayer)

Anti-Fibrotic Expectations and Concerns

• Animal studies show HIF-PHIs slow CKD progression
• Long-term HIF activation, however, carries risks: oncogenicity, aberrant angiogenesis, disturbed iron homeostasis
• Clinical success hinges on balancing acute activation (anemia correction) against chronic activation (fibrosis promotion)

HIF-2α–Selective Inhibitors: Belzutifan

• Merck's Welireg: FDA-approved in 2021 for VHL-associated renal cell carcinoma
• Targets HIF-2α dependency in RCC
• Repurposing for fibrotic indications (notably ADPKD — autosomal dominant polycystic kidney disease) is under active investigation

6. Use in Preclinical Research

Tissue-Specific HIF Knockouts

• Hif1a^flox/flox crossed with tissue-specific Cre lines (Alb-Cre liver, Sftpc-Cre lung, Pax8-Cre renal tubules, α-MHC-Cre heart)
• Dissects cell-type-specific HIF roles
• Global knockout is embryonic lethal — conditional KO is essential

HIF Activity Readouts

• Nuclear HIF-1α/2α IHC: direct visualization of hypoxic signaling
• Pimonidazole staining: functional hypoxia mapping
• HIF target gene panel: RT-qPCR of Vegfa, Pdk1, Car9, Slc2a1 (Glut1), Ldha
• HRE-luciferase reporter mice: longitudinal in-vivo HIF activity monitoring

In-Vitro Hypoxia

• Compare 1% O2 (hypoxia) vs 21% O2 (normoxia)
• Useful for hepatic stellate cell activation and myofibroblast conversion studies

7. FAQ

Q1: Can HIF-PHIs (like Roxadustat) serve as renoprotective drugs in CKD?

Animal models show renoprotective effects beyond anemia correction, but renal-function endpoints are not yet established in humans. The current positioning is "anemia correction with potential — but unproven — anti-fibrotic benefit." The US non-approval reflects ongoing cardiovascular safety concerns, and long-term risk/benefit analyses remain active.

Q2: Does HIF-1α or HIF-2α contribute more to fibrosis?

Context-dependent:

• Hepatic stellate cells and hepatocytes: HIF-1α dominant
• Proximal tubules and endothelium: HIF-2α dominant
• Pulmonary fibrosis: HIF-1α in fibroblastic foci, HIF-2α in vascular remodeling They overlap functionally, so fibrosis studies should measure both in parallel.

Q3: How do I build preclinical hypoxia models?

1. Hypoxic chamber housing (10% O2 for 4-8 weeks): pulmonary hypertension and cardiac hypertrophy
2. UUO model (UUO): rapid tubulointerstitial hypoxia
3. Repeat CCl4 dosing: recapitulates centrilobular liver hypoxia
4. In-vitro 1% O2 culture: cell-autonomous mechanism studies

Q4: Which HIF targets are most promising for drug discovery?

• Short to mid-term: HIF-2α–selective inhibitors (Belzutifan follow-ons, expansion into ADPKD and PPHN)
• Longer-term: cell-type-selective HIF modulators (targeted delivery to stellate cells, renal tubules, lung fibroblasts)
• Under debate: PHD inhibition combined with anti-fibrotics — acute HIF activation to correct anemia, then anti-fibrotic agents to prevent chronic downsides

Q5: How is HIF leveraged in MASH drug development?

Few current MASH trials directly target HIF, but existing MASH drugs such as Resmetirom modulate HIF pathways indirectly. Looking forward, combining HIF-PHIs with MASH therapeutics in patients with CKD comorbidity is an attractive future design.

---

Related Articles

• TGF-β/Smad Pathway — The master fibrosis regulator that reinforces HIF
• YAP/TAZ Mechanotransduction — Stiffness × hypoxia crosstalk
• Notch Signaling Pathway — HIF-downstream EMT/EndMT driver
• Fibrosis Mechanisms: Myofibroblasts as Drug Targets — Integrated mechanistic view
• MASH Model Selection Guide — Models that recapitulate zone 3 hypoxia
• UUO Renal Fibrosis Model — Standard renal hypoxia model
• IPF Treatment Landscape 2025 — Pulmonary fibrosis drug development

---

References

1. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17-25. PMID: 16291837
2. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. PMID: 22304911
3. Moon JO, et al. Reduced liver fibrosis in hypoxia-inducible factor-1α-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G582-G592. PMID: 19136383
4. Chen N, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011-1022. PMID: 31340116
5. Jonasch E, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036-2046. PMID: 34818478
6. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402. PMID: 18498744
7. Gunton JE. Hypoxia-inducible factors and diabetes. J Clin Invest. 2020;130(10):5063-5073. PMID: 32809974
8. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41-53. PMID: 23291219